Clears way for shareholder meeting on whether Southpointe generic pharmaceutical giant will proceed with takeover of Perrigo. Teva Pharmaceutical Industries on Monday ended its hostile bid for Mylan ...

Teva Pharmaceutical says rival generic drugmaker Mylan is engaging in a “desperate attempt” to keep its board and shareholders from considering Teva’s $40 billion-plus takeover offer. The claim, ...

NEW YORK (AP) — Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva’s mammoth deal for the generic drug business of Allergan. The Dutch drugmaker Mylan, ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: According ...

Ford's short vacation great for Alcoa's aluminum; F-35 gets ready for its closeup; Wolf's budget goes down to defeat in early vote; and gas prices may go down this summer. Here are five things to know ...

(Reuters) - Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more ...

Mylan NV said on Thursday, Aug. 25, it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary ...

(Reuters) - Generic drug maker Mylan NV's (MYL.O) $26 billion (17 billion pounds) hostile bid for peer Perrigo Company Plc (PRGO.N) looked unlikely to succeed late on Thursday, a few hours before it ...

WASHINGTON (Reuters) – Democrat Elizabeth Warren and 19 other U.S. senators voiced concern to the chief executive of Mylan NV about the high cost of its EpiPen on Tuesday, calling the device used in ...

Heather Bresch will face the proverbial lash from Congress on Wednesday over the escalating cost of Mylan NV’s EpiPen. Her boss won’t. Robert J. Coury acquired the rights to sell the emergency allergy ...

PITTSBURGH (AP) — The generic drugmaker Mylan is buying Abbott Laboratories’ generic-drugs business in developed markets for stock valued at about $5.3 billion. Mylan said Monday that the deal will ...